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Abstract: Although the measurement of dielectric properties of the skin is a long-known tool for
assessing the changes caused by nociception, the frequency modulated response has not been
considered yet. However, for a rigorous characterization of the biological tissue during noxious
stimulation, the bioimpedance needs to be analyzed over time as well as over frequency. The
3-dimensional analysis of nociception, including bioimpedance, time, and frequency changes, is
provided by ANSPEC-PRO device. The objective of this observational trial is the validation of
the new pain monitor, named as ANSPEC-PRO. After ethics committee approval and informed
consent, 26 patients were monitored during the postoperative recovery period: 13 patients with
the in-house developed prototype ANSPEC-PRO and 13 with the commercial device MEDSTORM.
At every 7 min, the pain intensity was measured using the index of Anspec-pro or Medstorm
and the 0–10 numeric rating scale (NRS), pre-surgery for 14 min and post-anesthesia for 140 min.
Non-significant differences were reported for specificity-sensitivity analysis between ANSPEC-PRO
(AUC = 0.49) and MEDSTORM (AUC = 0.52) measured indexes. A statistically significant positive
linear relationship was observed between Anspec-pro index and NRS (r2 = 0.15, p < 0.01). Hence,
we have obtained a validation of the prototype Anspec-pro which performs equally well as the
commercial device under similar conditions.
Keywords: post-operative pain; bioimpedance; time-frequency analysis; analgesia; anesthesia; drug
delivery control
1. Introduction
Pain is considered a subjective feeling (described by emotional aspects that influence pain
assessment scales) with objective roots (represented by the biological processes along the pain
pathway) [1]. Then, its management is generally based on assessment of the human body’s reaction to
noxious stimulation [2]. Since nociception is defined as the physiological encoding and processing
of nociceptive stimuli [3], the frequency modulation of the measured signal from the body should
be considered.
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Intraoperative analgesia or postoperative pain management requires to optimally be driven by an
objective assessment of the patient’s status, for avoiding the complication of intraoperative awareness
that continues to occur or for limiting the negative impact on postoperative hospital length of stay
and costs [4,5]. Several bio-markers have been studied in order to monitor the nociception level,
but these parameters lack an analysis in both time and frequency domain [6]. Consequently, we
have recently developed a device for pain assessment, namely ANSPEC-PRO. The prototype has
been validated on awake healthy volunteers undergoing induced pain, with successful results in
detecting and characterizing perception of pain [7]. The method is based on the detection of nociceptor
stimulation in the frequency-modulated skin impedance via non-invasive measurement in hand palm.
Although several commercially devices [2,8,9], as well as newly researched principles [10,11],
are currently available and clinically evaluated in many trials, no monitor is widely and routinely
used for analgesia assessment [12]. Hence, what differentiates Anspec-pro from the other available
devices is the mathematical formalism for parametric modelling of time-frequency variations of skin
impedance values [13]. Already developed methods show that changes in specific frequency ranges
have the ability to characterize the cortical activity (e.g., gamma frequencies of EEG signal by the
dimensionless index, WAVCNS [14,15]) or the parasympathetic nervous system (e.g., high-frequency
heart rate variability index [16]). Moreover, skin conductance is a long-known tool for quantifying the
sympathetic nervous system changes determined by immediate effect of pain, but not influenced by
hemodynamic variability [17]. Time-frequency scanning is a novel aspect that has not been yet assessed
for the skin-extracted electrical signals in nociception detection, but ongoing validation should soon
clarify its medical relevance. In addition, it has already been shown that mathematical formulation is
an important tool in characterization of drug tissue trapping [18]. The rationale of using bioimpedance
spectroscopy is that it allows a rigorous characterization of the biological tissue electrical properties
influenced by nociception [19,20]. The in-house developed prototype and methodology have the
advantage to follow a customizable input signal that excites the tissue over a range of frequencies.
The aim of this pilot study is to validate our impedance-based methodology for postoperative
pain evaluation. We primarily test the hypothesis whether the nociception measured by Anspec-pro is
correlated with the standard tool (i.e., numerical rating scale—NRS). Our secondary hypothesis is that
the specificity and sensitivity of Anspec-pro is similar to an existing device based on a similar approach
(skin conductance measurement), namely MEDSTORM. The skin sympathetic nervous system and
emotional sweating, mirrored by skin conductance response have been previously reported to assess
pain in patients, post-operatively [21] as well as perioperatively [22]. The patients for this trial were
equally distributed and randomly assigned to be evaluated with one of the two devices.
As such, the focus of the study is not to perform a comparison analysis between the developed
prototype and the commercial device. We need to validate Anspec-pro with an already approved device
that is based on similar methodology, under the same conditions. On long term, our methodology
will enable evaluation of pain by means of mathematical models which can be then included in a
fully automated drug delivery for anesthesia system [23–27]. Thus, the secondary objective of this
observational trial is frequency exploration of the tissue electrical properties influenced by nociception




The prospective observational study was approved by the Ethics Committee of Ghent University
Hospital (Protocol code: EC/2017/1517). The study has been registered before patient enrolment
at clinicaltrials.gov (Identifier: NCT03832764; principal investigator: M. N.; date of registration: 6
February 2019). This manuscript adheres to the applicable recommendations of Strengthening the
Reporting of Observational studies in Epidemiology (STROBE) statement [28].
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Written informed consent was obtained from each patient during their preoperative consultation
with the anesthesiologist. The course on Good Clinical Practice (GCP) has been completed by the
sponsor and each technician (also authors) that were operating the devices during this clinical trial for
data collection.
2.2. Patients
The trial was a cohort study performed between 24 April 2018 and 22 June 2018 at Ghent
University Hospital, Belgium. The patients included in the study were randomly chosen from the list
of the patients that were planned to have a surgical operation under general anesthesia, considering
inclusion/exclusion criteria approved through the protocol. The principal investigator evaluated the
eligibility for the patient’s enrolment, informed the prospective patient about the trial, and obtained
the informed consent. The patient allocation was made following simple randomization procedure to
1 of the 2 monitoring devices, using sealed opaque envelopes. On the day of surgery, the principal
investigator assigned the participants by asking them to choose between 26 identical envelopes
in which the Anspec-pro or the Medstorm choice was inside (13 envelopes with Anspec-pro and
13 envelopes with Medstorm). Patients were informed about the result and saw the monitor before
starting the procedures.
The inclusion criteria were as follows: (i) age between 18 and 75 years old, (ii) patients able
to comprehend, sign and date the written informed consent document to participate in the clinical
trial, (iii) patients planned for a surgical procedure under general anesthesia and expected to need
a strong analgesic, type opioid, like sufentanil, during the operation and (iv) American Society of
Anesthesiologists (ASA) physical status Class I–III classified by the anesthesiologist.
The exclusion criteria were as follows: (i) patients having epidural analgesia infused by a pain
pump, (ii) patients with chronic pain or getting medication used for chronic pain, like antiepileptics,
antidepressants, opioids; (iii) participation in a clinical trial within the past 30 days; (iv) operation
planned at one of the upper limbs (so that placing together the blood pressure cuff and the electrodes of
the pain monitor at the same upper limb would not be possible), (v) patients staying in daily hospital
or in Intensive Care Unit and (vi) pregnant women (the patient was asked before the operation). It
was stated that subjects must have been withdrawn under the following circumstances: (i) at their
own request, (ii) if the investigator feels it would not be in the best interest of the subject to continue,
and (iii) if the subject violates conditions laid out in the consent form/information sheet or disregards
instructions by the clinical investigation personal.
2.3. Study Protocol
The surgical schedule of Ghent University Hospital was assessed in order to determine subjects
who met the criteria for study enrolment. During all the three phases of the study (pre, intra, and
post-operative), all patients received care after local standards in all groups and the routine monitoring
was made. Care providers did not make changes to the used anesthetics based on the outcomes of
Medstorm or Anspec-pro devices.
The study protocol consisted of two periods of pain observation: (1) preoperative: in the waiting
room the patient’s pain was assessed by NRS (self-report) and also by the pain monitor for 14 min; this
data was used as a baseline for the measurements after the surgery; (2) postoperative: in Post-Anesthesia
Care Unit (PACU), the pain was measured like usual, thus by NRS (self-report or nurse evaluation at
every 7 min), but also by the pain monitor, continuously for 140 min. The measurement protocol is
depicted in Figure 1.
All patients of the two study groups had a general anesthesia during surgery. The performed
procedures were abdominal, gynecology, otorhinolaryngology, and urology. The general anesthesia
was done like standard care and the anesthetists chose the anesthetics and analgesics during the
operation. All medications were registered in the digital medical file of the patient. No changes to the
study protocol were made after trial commencement.
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Postoperative data collection included other candidate variables considered for statistical 
analysis: mean heart rate (HR) and non-invasive mean arterial pressure (MAP). 
The subjective conditions during the study have been reported for being considered in 
discussions and interpretation of results: GCS score (Glasgow coma scale), the movement of the 
patient, the location of the pain monitor electrode (left/right hand), all medications including dose 
and time of administration (pre-, peri-, and post-operative), medical and surgical history of the 
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Medstorm), (2) the NRS value from the patient (if totally awake) or from the nurse, (3) vital 
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Figure 1. Clinical trial protocol used for Anspec-pro device and Medstorm measurements for
pain monitoring.
2.4. Outcomes
The primary outcome parameters were the postoperative pain values, namely the Index of
Medstorm, the Index of Anspec-pro, and NRS. In the statistical analyses, the indexes of Medstorm or
Anspec-pro were considered dependent variables predicted from NRS values.
Secondary endpoints were the vital parameters and the ratings of subjective conditions (vigilance,
well-being, energy level, agitation, and nausea).
Postoperative data collection included other candidate variables considered for statistical analysis:
mean heart rate (HR) and non-invasive mean arterial pressure (MAP).
The subjective conditions during the study have been reported for being considered in discussions
and interpretation of results: GCS score (Glasgow coma scale), the movement of the patient, the
location of the pain monitor electrode (left/right hand), all medications including dose and time of
administration (pre-, peri-, and post-operative), medical and surgical history of the patient. The
medications were important to be documented in order to further correlate them in future analysis
with time-frequency changes in the measured impedance signal.
2.5. Data Collection
Each variable of interest has been measured and collected through the same protocol. Data
were derived from four sources: (1) the nociception index from the pain monitor (Anspec-pro or
Medstorm), (2) the NRS value from the patient (if totally awake) or from the nurse, (3) vital parameters
(blood pressure, heart rate, oxygen saturation) from the electronic medical record, (4) every real-time
observation that could influence the measurements from the device’s technician or nurse.
For tracking NRS, the patients were asked to quantify their level of pain on a numeric rating scale
(0–10). For the patients not fully conscious, the nurses reported the NRS value assessed for the patient
based on their experie c .
Standard care and medication were giv n like usual pre-, peri-, and post perative, e timated by
the experience of t nurse from rec very room or the anesthesiologist. The choice of the pain monitor
w s don by randomization, after the patient agreed to be part f the study.
Before the operation, the index from the pain monitor (after randomized sel ction), the NRS and
the vital parameters have been continuously monitored for 14 min. The values of these variables
were registered at each 7 min ( .g., minute 0, 7th, and 14th). The time interval h s been selected
together with the clinical i vestigator as an optimal interval for pain assessment. Hence, the choice of
7 min is al o a trade-off betw en the limitations given by the technology and the clinically applicable
interpretation. After this step, the surg ry was p rformed according to n rmal clinical procedures,
while the pati nt’s pain was not monitored with the p i device; the perioperative medications given
to the patient were noted i the personal file. Aft r the oper tion, the patient stayed in the recovery
room, getting the standard care from nurses. To determine th correlation betw en the index given
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by the pain monitor and the NRS value, all these parameters have been continuously monitored for
140 min. Thus, at each 7 min, the index from the pain monitor, the NRS, as well as the vital parameters
were noted (21 measurements in total, with the first one being measured in the first minute after the
patient was connected at the pain monitoring device in the recovery room).
The primary endpoints (pain level) were measured using the randomly assigned nociception
monitoring systems and NRS.
2.6. Monitors Used for Data Collection
One monitor was MED-STORM PAIN MONITORTM, ref: MD1001 (CE0413, Med-Storm Innovation,
AS, Oslo, Norway), which calculates the Skin Conductance Algesimeter [29]. The monitor generates
the number of fluctuations of skin conductance per second (NFSC) [17]. For this clinical trial, all the
procedures followed the instructions from Medstorm User Manual (Version 1.0 English) and the data
collection methods used in previous studies of NSCF in the postoperative setting [21]. Incoming data
were displayed on-line on a laptop connected to the monitor, on which the provided software from
manufacturer was previously installed. Data was collected and automatically analyzed in application
mode “Postoperative”. The manufacturer’s electrodes were placed at the hand palm of the patient
and connected with the monitor. The index NFSC is correlated by the manufacturer with NRS or VAS
(Visual Analogic Scale) score: the sensitivity to determine pain less than 3 or like 3 on the NRS/VAS has
the index less than or like 0.21 (peaks per second); the sensitivity to determine pain in the range 3–5 on
NRS/VAS scales has the index between 0.21–0.27 (peaks per second); the sensitivity to determine pain
in the range 6–10 on NRS/VAS scales, has the peaks per seconds more than 0.27.
The other monitor was ANSPEC-PRO (Ghent University, Ghent, Belgium—only for research use),
a new non-invasive pain monitor evaluated for the first time in a clinical trial (Approval FAMHP
no.: 80M0707, 03/04/2018). It has been previously validated on awake participants with self-induced
nociceptor excitation, after informed consent was given [7,30]. Anspec-pro injects in the skin a current
containing multiple frequencies via electrodes and measures the bio-modulated response voltage.
The proposed method is based on the fact that frequency affects the pain detection because each
tissue molecule has a different response to a given frequency, based on its electrical permittivity. This
permittivity decreases in three main steps corresponding to three dispersions: α: 10 Hz–10 KHz
characteristic for diffusion detection of the ionic species (extracellular fluid level), β: 10 KHz–10 MHz
for dielectric property measurement of the cell membrane, and γ > 10 MHz for content measurement
of the biological species (intracellular fluid level) [31]. Since pain is an electrical signal transmitted
by dynamics of ions signaling among intra- and extra-cellular fluid, the lowest frequency range was
firstly used. The diffusion of sodium/potassium ions changes the typical extracellular concentration,
resulting in a negative charged extracellular fluid, so an action potential can be seen as variations of the
electrical impedance of the tissue over the nociception pathway. The methodology for the prototype
development and measurements are detailed in [13]. The measurement requires three-point electrodes
applied on the palmar skin, as illustrated in Figure 2. The monitor is connected to a laptop and the
collected data is post-processed in order to generate the complex impedance using spectral analysis [30].
The aim of calculating the impedance is to obtain a pain index that will be further correlated with the
NRS given by the patient at every 7 min. The pain index is calculated as the mean of impedance values
over 7 min, where the impedance from each minute is also the mean of the values obtained from each
frequency (the device measures an output signal at 29 different frequencies, obtaining 29 values). The
result is an absolute value of the impedance, correlated with each BMI’s (body mass index) patient (the
considered index of Anspec-pro).
Both devices Medstorm and Anspec-pro are non-invasive pain monitors. Monitoring was not
blinded so that the observers could see the data collected curves and note when artifacts disturbed
the registration. When the signal quality was distortional as a result of change of the integrity of
the measured signal or temporary loss of connection, the event was registered as “artifact”, as were
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situations when the patient moved their measurement hand where the sensors were applied. In the
case of Medstorm, the device’s software automatically decides if the signal quality was bad.
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2.7. Potential Bias Reduction
Both nociception monitors measure bio-electrical data at the hand level, typically accounted as the
appropriate location to detect the micro-fluctuations in skin electrical permeability (caused by the fill
of plantar sweat glands under sympathetic control). Additionally, the post-operatory level of pain can
be influenced by the level of traumatology of the surgery. Consequently, we carefully considered the
type of intervention, including the part of the body concerned for the surgical procedure, as potential
sources of bias. Measures were taken to reduce bias by selecting patients for enrolment that were
planned for similar procedure types.
2.8. Statistical Methods
Given the fact there was no comparable previous stu y (that includes Ans ec-pro monitor), this
was pla ned as a pilot trial.
Statistical analysis was performed using Matlab Software (R2017a). Values are presented as number
of patients n (%), medians (interquartile ranges—IQR (range)) or mean (standard deviation—SD).
Analysis of variance (ANOVA) was used for accessing the intergroup differences between the outcomes
of the study.
The relationship between two variables was described by two methods: correlation and regression
analysis. The correlation analysis was performed based on the covariance as a measure of how much
two random variables vary together. The values of the correlation coefficients (r) can range from −1 to
1, with −1 representing a direct, negative correlation, 0 representing no correlation, and 1 representing
a direct, positive correlation. Linear regression was used to investigate if one variable can be predicted
from another, by assessing the coefficient of determination (r2). A receiver-operating characteristic
(ROC) curve was built by plotting the sensitivity, or true positive rate, as a function of the false positive
rate (1-specificity). The area under a ROC curve (AUC) represents the predictive ability of the test and
should be at least 0.75 for good prediction. Statistical significance was accepted for p < 0.05.
3. Results
The principal investigator scr ened 26 patients scheduled for different surgeries und r general
anesthesia in the operation theatre of Ghent University Hospital. A flow diag am d noted in Figure 3
s ows the details of assessment and exclusio . Tw nty-six patients were enrolled in the study; data
from four patients was excluded because: fo one patient the measurement was interrup ed during th
post-anes sia monitoring and data missed; for three pat ents, the da a enre istered artefacts.
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For statistical analysis, data from 22 patients was included. Subject demographics and
characteristics are shown in Table 1. Age, height, weight and BMI were not significantly different
(p > 0.2) between the two groups.
Table 1. Patients characteristics and clinical data.
Characteristic ANSPEC-PRO (n = 11) MEDSTORM (n = 11)
Biometric data
Age (y) 34.90 (12.46) 41.54 (18.26)
Height (cm) 167.45 (10.01) 173.72 (12.58)
Weight (kg) 69.72 (13.38) 74.18 (17.41)
BMI (kg·cm−2) 24.81 (4) 24.24 (3.2)
Gender n (%)
Male 1 (0.09) 6 (0.54)
Female 7 (0.63) 4 (0.36)
Transman 3 (0.27) 1 (0.09)
Surgery type n (%)
ORL 3 (0.27) 5 (0.45)
Abdominal 2 (0.18) 1 (0.09)
Gynecology/Urology/Orthopedics 5 (0.45) 5 (0.45)
Breast surgery 1 (0.09) 0
ASA class n (%)
I 3 (0.27) 4 (0.36)
II 8 (0.72) 6 (0.54)
III 0 1
Values are means (SD)—95% confidence intervals)—respectively counts (%) from total number of patients of the
group monitored with the same device; BMI—Body Mass Index; ORL—Otorhinolaryngology; ASA—American
Society of Anesthesiologists physical status.
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The postoperative clinical data acquired in PACU is summarized in Table 2. The mean of each pain
index was not considered for analysis, having non-comparable magnitudes. The methods of calculation
for each pain index are different, resulting in an absolute value of the complex impedance as a function
of frequency (Anspec-pro method) and a number of skin fluctuations per second (Medstorm method).
The NRS score (median (interquartile range (range))) was significantly higher in the Anspec-pro group
than in Medstorm (4 (2–6 (0–9)) versus 2 (0–3 (0–8)), p < 0.001). In addition, the vital parameters (MAP
[mmHg], HR [beats·min−1] were significantly lower in Anspec-pro group compared with Medstorm
group (p < 0.001).
Table 2. Postoperative outcome parameters in post-anesthesia care unit (PACU).
Variables ANSPEC-PRO GROUP(n = 11)
MEDSTORM GROUP
(n = 11) p-Value
Pain index from device 1.31 (1.14–6.56(0.71–38.48)) 0.07 (0–0.2 (0–0.73)) <0.001
NRS 4 (2–6 (0–9)) 2 (0–3 (0–8)) <0.001
HR [Beats/min] 68 (59–77.5 (40–99)) 74.5 (65–84 (46–107)) <0.001
MAP [mmHg] 86.66 (78.66–93.5(63–113))
91.66 (84.66–97.83
(72–116)) <0.001
Values are median (IQR (range)) from total number of patients of the group monitored with the same device;
PACU—Post-Anesthesia Care Unit; NRS—11 points Numeric Rating Scale (0–10); HR—Heart Rate; MAP—Mean
Arterial Pressure.
The correlation analysis showed no significant relationship between the pain indexes from devices
and NRS, neither in the Anspec-pro group nor in the Medstorm group (correlation coefficient r = 0.39 in
Anspec group vs. r = −0.066 in Medstorm group, p = 1). No significant correlation was found between
Anspec-pro index and HR (r = 0.068, p = 1) or Anspec-pro index and MAP (r = 0.13, p = 1). The correlation
was statistically non-significant as well between Medstorm index and HR (r = 0.29, p = 1) or Medstorm
index and MAP (r = 0.04, p = 1).
A statistically significant positive linear relationship (IndexAnspec-pro = −0.58 + 1.8018 × NRS, r2 =
0.15, p < 0.01) was observed between Anspec-pro index and NRS during the stay in PACU, with 15% of
the variance in Anspec-pro index predicted by NRS, as seen in Figure 4a. On the other hand, the linear
relationship between Medstorm index and NRS assessed during PACU observations had no statistical
significance (IndexMedstorm= 0.12 − 0.004 × NRS, r2 = 0.004, p = 0.328), as depicted in Figure 4b.
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The ROC curve determining the performance of Anspec-pro index respectively of Medstorm for
predicting NRS is shown in Figure 5. The sensitivity and specificity of Anspec and Medstorm methods
were similar, as the area under the curve for Anspec-pro (AUC = 0.49) was non-significantly different
from the one of Medstorm device (AUC = 0.52).
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4. Discussion
The results of this pilot study demonstrate that non-significant differences were reported for
specificity-sensitivity analysis between ANSPEC-PRO and MEDSTORM measured indexes. Hence, we
have obtained a validation of the prototype Anspec-pro which performs equally well as the commercial
device under similar conditions. The AUC for Medstorm was 0.52 and for Anspec-pro it was 0.49. The
correlation analysis showed no significant relationship between the pain indexes from devices and
NRS, neither in the Anspec-pro group nor in the Medstorm group (with correlation coefficient r = 0.39
respectively r = −0.066). In addition, no significant correlation was found between Anspec-pro index
or Medstorm index and the monitored vital parameters (HR and MAP). Even small, a statistically
significant 15% of the variance in Anspec-pro index was predicted by NRS, while no statistically
significant linear relationship was observed between Medstorm index and NRS (r2 = 0.004). Although
the NRS is the golden standard nowadays to measure pain, we see that the ROC-curve for the two
monitors is not conclusive, perhaps since both are sensitive to artefacts (e.g., movements). Further
adaptation of the software according to the physiological parameters, like including an NRS-guided
algorithm may be an interesting next step.
Artificial intelligence has been advancing in anesthesiology, including depth of anesthesia
monitoring, control infusion, or pain management [33]. However, despite decades of research on
optimal pain management, postoperative pain continues to be inadequately treated [34,35]. The almost
ubiquitous acute pain after surgery that mostly resolves within one week can persist beyond the
usual time of recovery and transform into a chronic pain state [36]. Major causes of this problem are
inadequate pain assessment and lack of clear guidance [37]. Globally, the massive volume of surgery
represents a vast potential for postsurgical pain, with a rise from 234 million operations (2004) to
313 million (2012) [38]. Therefore, analgesia monitoring that provides well-tolerated pain relief after
surgery is of utmost importance.
Besides biomarkers for pain detection under general anesthesia [16], modelling of physiological
nociception and drug pharmacokinetics/pharmacodynamics (PK/PD) have a significant impact on
anesthesia drug administration [39,40]. The performance of the traditional target-controlled infusion
systems for anesthesia can be improved by the real-time adaptation of PK/PD models [41–43]. This
is provided by the closed-loop feedback systems that integrate the pharmacological and effect
modelling [44–47]. However, the drug-dose relationship for analgesia still lacks a direct PD model to a
pain monitor, propofol and remifentanil being mostly linked to BIS (Bispectral index) [42,48,49]. This
can be represented by a Hill curve using the output from the commercial devices or our prototype,
while the last one enables the use of transfer function to evaluate the analgesia state of the patients
more in detail (e.g., by using the frequency response).
To measure is to know. This is a very well understood concept across all disciplines. Frequency
response allows one to determine approximate models for the process at hand. These procedures
usually require multiple or persistent exciting tests with input signals of various frequencies, so that the
frequency response can be estimated over the required frequency range [50]. In this particular case, the
essential benefit of the ANSPEC-PRO device is that it allows a customizable input signal to the system
under observation. In the particular studies case, the ANSPEC-PRO sends a composed multisine with
optimal crest factor for optimal extraction of dynamic process information for identification purpose of
a process model [13]. MEDSTORM, by contrast, has a single sine input at a single frequency, and the
recorded signal back from the skin impedance is not processed as a function of frequency (due to its
single point data) but in the time domain, using a moving window averaged amplitude correlated
with the pain and awareness in the patient. The disadvantage is that at the cost of the same measuring
principle, a great deal of opportunity to gather more information without any extra cost for the patient
remains unexplored. It is here that the Anspec-pro excels, i.e., it has a multiple point in frequency signal
recording data, thus allowing extraction of a dynamical frequency response which can be evaluated
also as a function of time, i.e., a time-frequency analysis of the skin impedance to be correlated to
J. Clin. Med. 2020, 9, 684 11 of 14
pain levels. Our future publications will present the frequency analysis of nociception from a more
engineering-centered point of view.
It is not our claim as to whichever device is better. Since they both use the same measuring
principles and sensors (i.e., skin impedance data), the difference is more intrinsically in the amount
of data collected and post-processing. We hypothesize that the skin impedance is a dynamic system,
where dynamic processes occur as a function of noxious stimulation and of opioid effects. By definition
of system engineering principles of identification, characterization of a dynamic process requires a
persistent excitation: in our case the multisine signal composed of sum of sinusoids in a bandlimited
frequency interval. This allows to extract a transfer function of the process, i.e., a function which
characterizes the dynamical processes taking place. A transfer function can never be defined by a
single frequency point, as is the case with MEDSTORM. Hence, with ANSPEC-PRO, the user has
more information to process, with a prospective higher degree of usefulness for clinical research. It
was not our purpose to propose yet another pain monitor on the market, but rather to introduce the
rationale and the means to the clinical research community for performing more in-depth analysis of
the complex pain pathway monitoring process.
Our study presents, however, some limitations. Factors such as postoperative cofounders (i.e.,
movements, anxiety) influence skin electrical properties in awake subjects. Additionally, our results
may not be extrapolated to any category of patients (i.e., different analgesic drugs have been used
without an effect analysis of these drugs on the monitored pain index).
5. Conclusions
In conclusion, we merely wanted to verify that the proposed versatile instrumentation delivered
by ANSPEC-PRO and methods used to extract information via skin impedance have meaningful
clinical results. This assumption has been successfully verified as it delivers similar results to a
commercial device, i.e., MEDSTORM. Through the availability of the ANPSEC-PRO instrumentation
and methodology, there is a great opportunity to push-through technology and clinical state of art
for pain monitoring and related research. Future research opportunities are related to the biomedical
engineering domain through the analysis of the frequency response function which better characterizes
the nociception dynamical process.
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